Evernest Financial Advisors LLC Grows Stock Position in Eli Lilly and Company $LLY

Evernest Financial Advisors LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,878 shares of the company’s stock after purchasing an additional 99 shares during the quarter. Eli Lilly and Company makes up approximately 1.2% of Evernest Financial Advisors LLC’s holdings, making the stock its 20th biggest position. Evernest Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $3,803,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Hobbs Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC lifted its holdings in shares of Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after purchasing an additional 12 shares during the period. O Brien Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after purchasing an additional 12 shares during the period. Ascent Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after purchasing an additional 12 shares during the period. Finally, Tennessee Valley Asset Management Partners lifted its holdings in shares of Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock worth $407,000 after purchasing an additional 13 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Up 1.7%

Shares of LLY stock opened at $826.20 on Thursday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market cap of $781.97 billion, a price-to-earnings ratio of 54.00, a PEG ratio of 1.16 and a beta of 0.47. The stock has a 50 day simple moving average of $745.96 and a 200-day simple moving average of $766.28. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Morgan Stanley decreased their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.